View clinical trials related to Hypoparathyroidism.
Filter by:Observational, multicenter, national, cross-sectional study aiming to describe the epidemiological clinical, biological and therapeutic profile of patients suffering from defect in secretion (hypoparathyroidism) or action (pseudo-hypoparathyroidism) of parathyroid hormone.
The aim of this observational study is to learn about long term effects to post surgical hypoparathyroidism. The main questions are: 1. Patients with hypoparathyroidism do not have an increased arterial stiffness compared to healthy controls. 2. Patients with hypoparathyroidism do not have an increased coronary artery plaque burden assessed by cardiac CT compared to healthy controls. 3. Patients with hypoparathyroidism do not have an increased prevalence of vertebral fractures compared to healthy controls. Results will be compared with gender and age matched controls from the general population. Participants will have a CT scan, DXA scan, tonometry, blood samples and questionaries performed and collect a 24-hour urine sample.
The idea of the project is to develop a method of treatment of postoperative hypoparathyroidism using cultured allogenic parathyroid cells.
Background: The Calcium-Sensing Receptor (CaSR) detects the amount of calcium in the blood and urine. Parathyroid hormone (PTH) helps keep blood calcium levels normal. When PTH and calcium blood levels are low, this is called hypoparathyroidism. People with changes in the CaSR have a type of hypoparathyroidism called ADH1. ADH1 is treated with calcium supplements and vitamin D. But these do not always work, and can cause problems like kidney stones. Researchers want to see if the drug CLTX-305 is a better treatment option. Objective: To see if CLTX-305 is safe and works in people with ADH1. Eligibility: People ages 16 and older with ADH1 Design: Participants will be screened with: Medical history Physical exam Kidney ultrasound: Participants will lie on a table while a wand is moved over their back. Bone density test: Participants will lie on a table while an X-ray machine moves around them. Blood, urine, and heart tests The study is split into 3 periods. Participants may take part in some or all periods. In Periods 1 and 2, participants will take CLTX-305 by mouth once or twice daily for up to 5 days. Participants will stay at the NIH for 7 days and 6 nights. In Period 3, participants will take CLTX-305 at home for 24 weeks. They will have 3 inpatient visits that last 1 2 days each. Screening tests will be repeated during the study. Blood and urine will be collected often. Participants dose of calcium and vitamin D may be changed. They may be asked to stop taking other medicines or change the dose.